Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, James K. Schwarz

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.

Original languageEnglish (US)
Pages (from-to)508-514
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number5
DOIs
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation'. Together they form a unique fingerprint.

  • Cite this